Drug
Ava
Ava: highest development phase Post-Market, developed by Emergent BioSolutions. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| AVA NCT02339155 | Post-Market | Infections, Bacterial |
| AVA NCT01979406 | Phase 1 | Anthrax Infection |
Latest
No recent events.
Follow Ava on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.